PubMed · 8480809
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
J Juchniewicz. 1993. Selecting a QA glucose meter.. https://doi.org/10.1097/00000446-199304000-00029
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
BACKGROUND: Home glucose monitoring system is increasingly recognized as an important tool for glycemic control. We evaluated the clinical performance of the eBsensor glucose monitoring system. METHODS: Fingertip capillary blood glucose concentrations from 282 subjects were measured using eBsensor glucose monitoring system and compared against predicate devices and the Yellow Springs Instruments (YSI) 2300 blood glucose analyzer. Accuracy and precision of the eBsensor glucose monitoring system were assessed using several methods. The comparative study between the eBsensor and 2 currently marketed monitoring systems was performed. RESULTS: The 282 eBsensor readings covered a wide range from 2.6 to 24.4 mmol/l. Deming regression and Pearson correlation analyses showed a linear relationship between the eBsensor readings and the YSI reference method (eBsensor=0.9496 YSI+0.4127 mmol/l; r=0.98). Error Grid analysis demonstrated that 100% of the eBsensor readings in clinically acceptable zones A and B. The CVs for the 6 lots of strips were within the satisfactory interval (<6%). The comparative study showed that the eBsensor readings correlated well with the OneTouch Ultra values (r=0.97) and the Glucocard II values (r=0.97). CONCLUSIONS: eBsensor is a reliable glucose monitoring system which provides high accurate and precise glucose readings over a wide range of glucose concentrations.
UNLABELLED: It is extremely difficult to assess the prevalence and the total costs of diabetes mellitus for the German health care system. The last sound assessment of the total costs is based on the CODE-2 study, although this study reflects the situation in 1998. METHODS: In this paper we assess again the total costs of diabetes mellitus type 2 and self measurement of blood glucose (SMBG) for the German healthcare system, based on the analysis of a recently published retrospective, multicentre trial dealing with the impact of SMBG on long-term patient outcomes. RESULTS: Overall, yearly costs for the treatment of diabetes mellitus type 2 and its complications amount to Euro 3 196,-per patient. This equals 4.6% to 8.2% of the German healthcare expenditure, in relation to the estimated prevalence of the disease in Germany. The cost difference between the cohorts with and without SMBG was not essential (Euro 290,-higher costs in the cohort with SMBG). CONCLUSIONS: From a public health standpoint, prevention of diabetes mellitus or at least prevention of its complications by optimising glucose metabolism should be given highest priority in times of limited resources for healthcare. SMBG is perhaps a valuable tool to achieve this target.